DXCM
DexCom, Inc. · Healthcare · Medical - Devices
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 166 | +2 | 299.42M | $20.12B | +7 | −7 |
| Q1 2026 | 169 | 0 | 297.37M | $18.71B | +3 | −4 |
| Q4 2025 | 168 | 0 | 314.09M | $20.85B | +1 | n/a |
| Q3 2025 | 26 | +1 | 175.97M | $11.84B | +1 | −1 |
| Q2 2025 | 23 | -1 | 152.74M | $13.33B | n/a | −1 |
| Q1 2025 | 21 | 0 | 61.18M | $4.17B | n/a | n/a |
| Q4 2024 | 21 | +1 | 69.06M | $5.37B | +1 | n/a |
| Q3 2024 | 19 | -2 | 54.56M | $3.66B | n/a | −2 |
| Q2 2024 | 21 | n/a | 52.99M | $6.01B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford ✦ | 15.33M | n/a | $1.74B | 1.4% | n/c | 1 | SEC ↗ ×4 |
| 2 | Geode Capital Management ✦ (passive) | 9.72M | n/a | $1.10B | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 3 | Capital World Investors ✦ | 8.31M | n/a | $942.19M | 0.2% | n/c | 1 | SEC ↗ |
| 4 | Norges Bank ✦ (passive) | 5.39M | n/a | $611.04M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 5.33M | n/a | $604.48M | 0.1% | n/c | 1 | SEC ↗ ×12 |
| 6 | T. Rowe Price ✦ | 3.45M | n/a | $391.15M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | Tiger Global Management ✦ | 1.15M | n/a | $130.71M | 0.6% | n/c | 1 | SEC ↗ |
| 8 | Fisher Asset Management ✦ | 773.87K | n/a | $87.74M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 752.32K | n/a | $85.30M | 0.2% | n/c | 1 | SEC ↗ ×2 |
| 10 | Citadel Advisors ✦ | 727.88K | n/a | $82.53M | 0.1% | n/c | 1 | SEC ↗ ×3 |
| 11 | Renaissance Technologies ✦ | 462.57K | n/a | $52.45M | 0.1% | n/c | 1 | SEC ↗ |
| 12 | Adage Capital Partners ✦ | 389.00K | n/a | $44.10M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | Marshall Wace ✦ | 351.31K | n/a | $39.83M | 0.1% | n/c | 1 | SEC ↗ ×3 |
| 14 | Bridgewater Associates ✦ | 347.32K | n/a | $39.38M | 0.2% | n/c | 1 | SEC ↗ |
| 15 | Soros Fund Management ✦ | 166.80K | n/a | $18.91M | 0.6% | n/c | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 85.02K | n/a | $9.64M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 17 | Millennium Management ✦ | 64.49K | n/a | $7.31M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Arrowstreet Capital ✦ | 54.97K | n/a | $6.23M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | GAMCO Investors ✦ | 52.00K | n/a | $5.90M | 0.1% | n/c | 1 | SEC ↗ |
| 20 | Gotham Asset Management ✦ | 47.88K | n/a | $5.43M | 0.1% | n/c | 1 | SEC ↗ |
| 21 | D. E. Shaw & Co. ✦ | 35.74K | n/a | $4.05M | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 15.50K shares, $973 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.56K sh · $220,975
Director · 6.54K sh · $549,538
Officer · 1.70K sh · $142,868
Director · 1.55K sh · $130,231
Officer · 3.64K sh · $302,936
Officer · 2.56K sh · $226,669
Officer, Director · 19.31K sh · $1.73M
Officer, Director · 97 sh · $8,867
Officer, Director · 7.35K sh · $667,332
Officer · 1.70K sh · $156,281
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology